Earnings Call Intelligence Subscribe
Home › Call Sheets › IDXX › Q3'25
Call sheet · Q3'25

IDEXX Laboratories (IDXX)

Q3'25 earnings call · held November 3, 2025 · compared with the Q2'25 call · management-credibility review
11/12
Disclosure score
1 medium, 5 low flags
Financial quality
Bottom line
The sleeper story is international markets driving 14% growth without the new innovations - this is raw sector development paying off and suggests IDXX has cracked the code on international expansion. While everyone focuses on InVue and Cancer Dx, the real growth engine may be overseas where diagnostic penetration is still 'embryonic.' The obvious headline is strong Q3 beats, but the binding constraint remains U.S. clinical visit pressure despite aging pets starting to help. Management's most telling quote: 'We're assuming U.S. clinical visits continue to decline at levels moderately better than the year-to-date average' - they're not banking on the improvement they just reported. My view changes if international growth sustains above 12% for two more quarters - that would signal a genuine long-term growth reacceleration beyond just U.S. recovery.

The 30-second version

  • International CAG recurring revenue hit 14% - highest since COVID - WITHOUT InVue or Cancer Dx
  • InVue hitting $3,500-$5,500 per analyzer utilization target but Q4 placements guide implies sequential slowdown
  • U.S. clinical visits improving but guidance assumes 'modestly better than year-to-date average'

What changed this quarter

MetricQ2'25Q3'25Change
Revenue (organic)9% (vs 8% YoY prior year)12% (vs 11% YoY prior year)+300bps acceleration, strongest in over a year
CAG Diagnostics Recurring Revenue (organic)~7.5% (vs 6% YoY prior year)10% (vs 8% YoY prior year)+250bps acceleration
International CAG Recurring Revenue (organic)11% (double-digit)14% (including ~1% days benefit)+300bps to highest since COVID
U.S. CAG Recurring Revenue (organic)6% (vs prior trends)8% (vs prior trends)+200bps improvement
U.S. Same-Store Clinical Visits-2.5% decline-1.2% decline+130bps improvement, best trend in quarters
VetLab Consumables Revenue (organic)14% (double-digit)16% (double-digit)+200bps acceleration
CAG Instrument Revenue (organic)62% growth71% growth+900bps acceleration on InVue ramp
Premium Instrument Placements6,070 units (+23% YoY)5,665 units (+37% YoY)Lower absolute but higher YoY growth rate
InVue Dx Placements (quarterly)2,388 units1,753 unitsSequential decline but within expected range
InVue Dx Placements (YTD)~2,700 through June4,400+ through SeptemberStrong acceleration, raising FY guide to 6,000

Accountability tracked

8 new promises made5 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full IDXX Q3'25 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.